SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Addition of Bamlanivimab and Casirivimab/Imdevimab as a Texas Medicaid Benefit and for FDA Emergency Use Authorization
Attention: All Providers Effective Date: December 15, 2020Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Texas Children’s Health Plan would like to inform network providers that Texas Medicaid has added two medications, bamlanivimab and casirivimab/imdevimab, as outpatient benefits in response to the COVID-19 Emergency Use Authorization (EUA). Both are monoclonal antibodies used to treat COVID-19 and should be administered within 10 days of symptom onset. Qualifications to receive this medication include the following:
Mild to moderate coronavirus disease (COVID-19) with a diagnosis of U07.1
Patients twelve years old and older
Patients with a weight of at least 40 kg or 88 pounds
Patients that are at a high risk of progressing to severe COVID-19 or requiring hospitalization
These medications are not recommended for patients that have been hospitalized due to COVID-19 or require oxygen therapy.
How this impacts providers: The following codes will be set up as payable:
Bamlanivimab (Q0239) and the administration of bamlanivimab (M0239). It is an allowable drug for dates of service on or after November 9, 2020.
Casirivimab/imdevimab (Q0243) and the administration of casirivimab/imdevimab (M0243). It is an allowable drug for dates of service on or after November 21, 2020. Casirivimab and imdevimab must be administered together.
